Skip to content
Nanopharm-logo-with-signature-Pantone (1)
  • Home
  • About Us

    About Us

    Leadership Team

    Our Scientists
  • Services

    Product Development

    Preformulation & Preclinical

    Formulation & Drug Product Development

    Clinical Development

    Clinical Trial Manufacturing

    cGMP Release & Stability Testing

    Analytical Services

    Research & Development

    Spray Characterization

    Method Development
    cGMP Release & Stability

    IVBE & CMC Studies

    Alternative Bioequivalence

    In-Silico Modeling

    SmartTrack™

    PBPK Modeling

    Regional Deposition Modeling

    Regulatory

    Consultancy

    Alternative Bioequivalence
  • OINDP Expertise

    Nasal

    Nasal Powders

    Nasal Sprays

    Nasal Cast Deposition

    Inhalation

    DPI

    pMDI

    Low GWP Propellant pMDI

    Nebulizers

    Inhaled Biologics

    Generics & Lifecycle Management

    Reformulation & Repositioning

    IVBE

    Alternative Bioequivalence
  • Resources

    Resources

    Scientific Publications

    White Papers

    Posters
  • News & Events
  • Contact Us
  • Careers

Resource Type: Innovation & Insights

Nasal Drug Development, Trends and Challenges with Nasal Formulations

Nanopharm explores the current trends and technical challenges in nasal drug product development, focusing on formulation.

Nanopharm: cGMP Drug Development in OINDP

Nanopharm expands with cGMP facilities for advanced drug development in OINDP. Specializing in biologics characterization and particle engineering.

A respirable HPV-L2 dry-powder vaccine with GLA as amphiphilic lubricant and immune-adjuvant

Discover Nanopharm’s breakthrough in dry-powder HPV vaccines. Learn how GLA enhances aerodynamic performance for effective inhalation delivery of the antigen.

Nanopharm’s Nasal Spray for SARS-CoV-2 Antibody Treatment

Discover Nanopharm’s innovative nasal spray for SARS-CoV-2. Learn how this prophylactic treatment effectively delivers antibodies for maximum protection.

Nanopharm & Leyden – OINDP Intranasal Sprays vs. Respiratory Viruses

Nanopharm & Leyden Labs collaborate on intranasal sprays for broad protection against respiratory viruses. Focused on OINDP drug development.

Fundamental properties of propellant aerosols can guide transition to low global warming potential pMDIs: size, velocity and surface charge

Discover Nanopharm’s groundbreaking research on Low GWP propellants in pMDIs. Learn how they revolutionize drug delivery and the role of valve and actuators.

Nanopharm: Valve Types & Container Systems in pMDIs with Salmeterol

Explore Nanopharm’s study on the impact of valve types and container closure systems in pMDIs. Focus on formulations with Salmeterol Xinafoate and how they perform under stressed conditions.

Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate?

Understand how particle size impacts inhalation drug delivery and the role of dry powder inhalers (DPIs) in treating respiratory diseases.

The Role of In Silico Regional Deposition Modelling and Pharmacokinetic Profiling in the Development of a Generic Tiotropium Dry Powder Inhaler

Nanopharm explores In Silico methods in the development of a Generic Tiotropium Dry Powder Inhaler (DPI). Learn how drug absorption is impacted.

The influence of blend composition on the aerodynamic performance of a novel high resistance multi-dose device

Explore the study by Irene Rossi on blend composition’s influence on Aptar Prohaler®. Insights into FPM, MMAD, and aerodynamic performance in COPD treatment

← Previous
Next →
  CONTACT
+44 (0) 1633 372200
info@nanopharm.co.uk

Nanopharm Ltd
Franklin House, Grange Road, Cwmbran, NP44 3WY, United Kingdom   

STAY CONNECTED

Linkedin Youtube
General Terms and Conditions of Use and Privacy Policy
Terms & Conditions of Sales

© 2024. Nanopharm Ltd. All rights reserved.